Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577149 | 0.92 | FFAR1 (0.48) | PARP10NR4A2PTGESALOX5 | |
| SCHEMBL3588588 | 0.91 | ALOX5 (0.52) | MAOBPARP10NR4A2MMP13ADAMTS4 | |
| SCHEMBL3589183 | 0.89 | PARP15 (0.53) | MAOBPARP10MMP13ADAMTS4MAOA | |
| SCHEMBL3595967 | 0.86 | HSD17B2 (0.50) | NR4A2PTGESALOX5 | |
| SCHEMBL3588841 | 0.83 | FFAR1 (0.47) | PTGESALOX5 | |
| SCHEMBL3589161 | 0.80 | HSD17B2 (0.45) | PTGESALOX5 | |
| SCHEMBL3584964 | 0.80 | F7 (0.44) | PTGESALOX5 | |
| SCHEMBL3591193 | 0.79 | ADAMTS4 (0.41) | ADAMTS4PTGESMMP2MMP9 | |
| SCHEMBL2246956 | 0.78 | GRM5 (0.57) | MAOBPARP10NR4A2MMP13ADAMTS4 | |
| SCHEMBL4649130 | 0.77 | MMP2 (0.40) | PTGESALOX5MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | claimed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | claimed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | MAOB 2020/4885PARP10 1677/4885NR4A2 3238/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | MAOB 2020/4885PARP10 1677/4885NR4A2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.